drugset / Trial / NCT04644107

Expanded Access for Marizomib

NCT04644107

Expanded access No longer available Celgene Corporation

Summary

This is an expanded access program (EAP) for eligible participants designed to provide access to Marizomib.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Background Marizomib Small molecule Intravenous

Indications